|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.48 USD | 0.00% |
|
+0.07% | +15.96% |
| 06-29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Neutral | Neutral |
| Resistance | 20.75 | 25.25 | 35.73 |
| Spread/Res. | -1.42% | -18.99% | -42.75% |
| Spread/Supp. | +10.45% | +25.49% | +23.22% |
| Support | 18.52 | 16.3 | 16.6 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ZLAB Stock
- Charts Zai Lab Limited
Select your edition
All financial news and data tailored to specific country editions
